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Orally-ingested aluminum compounds have been implicated
in the development of dialysis encephalopathy, osteomalacic
dialysis osteodystrophy and other disorders in both hemodia-
lyzed and nonhemodialyzed patients suffering from chronic
renal failure [1—10]. Both dialysate aluminum content [7, 11, 12]
and aluminum-containing phosphate binding agents [12—15]
have been identified as contributing to hyperaluminemia in
uremic patients. The health threat from dialysate fluids has been
reduced by the recommendation that the dialysate contains less
than 10 gig/liter of aluminum [16]. Alternative phosphate-
binding agents which do not contain aluminum are available but
these agents are not free of problems [17], and uremic patients
continue to ingest significant doses of aluminum-containing
phosphate binding agents.
Aluminum is the most common metal in the biosphere of
humans but, aside from uremic patients, causes no widespread
toxicity. This may be as a result of the extremely limited
solubility of aluminum at the pH range of the small intestine and
blood [18]. Advances in analytical chemistry have made it
possible to measure picogram quantities of aluminum in body
fluids, thus enabling accurate determination of plasma alumi-
num levels in the part per billion (zg/liter) range. These analyt-
ical techniques have shown that orally ingested aluminum-
containing antacids elevate plasma aluminum levels in man [13].
Balance studies monitoring aluminum absorption and elimina-
tion revealed an average positive balance from 23 to 313 mg of
aluminum per day when diets were supplemented with 1 to 3 g
of aluminum per day [15]. These studies show that a small
fraction of the ingested aluminum is absorbed. This absorption
presents potential toxic effects to uremic patients whose ability
to eliminate aluminum is impaired.
In addition, Slanina et al [19] have shown that addition of
citric acid to aluminum-supplemented dietary regimens results
in blood aluminum levels that are significantly higher than those
found in subjects treated with aluminum-supplemented dietary
regimens alone. This result suggests that dietary factors may
contribute to aluminum absorption.
This study was undertaken to determine if the form of
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aluminum present in the intestinal lumen significantly affects
the absorption of aluminum following oral ingestion.
Methods
Perfusions of in situ rat gut preparations [20] were performed
within a laminar flow hood in order to prevent contamination of
samples. All glass and plasticware was soaked overnight in 50%
concentrated nitric acid, washed with distilled water and oven
dried before use. Perfusate solutions contained NaCI (140 mM/
liter), KCI (4.56 mM/liter), and CaCI2 (1.25 mM/liter), as well as
2.5 X l0 M aluminum chloride and equimolar sodium citrate,
where indicated. The aluminum chloride concentration was
selected to represent the midpoint between the amount of
aluminum estimated to be in the diet in the absence of an
aluminum-containing phosphate binding agent, 8 to 80 mg
equivalent A1203 [21], and the 500mg of equivalent A1201 in the
normal dose of an aluminum-containing phosphate binding
agent [22]. If it is assumed that the aluminum-containing com-
pound is dispersed in 300 ml of gastric fluid [23], then the
expected aluminum concentration range in the gastric fluid
would be 2.5 x l0— to 2.5 x 102 M.
Male Wistar rats (275 to 375 g) were fasted for 12 hours and
then anesthetized with pentobarbital, 50 mg/kg. Intestinal can-
nulas were placed below the ligament of Trietz and proximal to
the ileocecal juncture. The intestinal segment was then care-
fully returned to the peritoneal cavity, and the abdominal
opening closed with sutures.
Renal arteries were ligated in order to prevent elimination of
absorbed aluminum.
A 25 ml volume of perfusate containing 2.5 X 10—2 M
aluminum chloride at an initial pH of 3.2 was transferred to a
jacketed beaker which was maintained at 37°C. The perfusate
was stirred continuously and circulated (Polystaltic pump,
Buchler, Fort Lee, New Jersey) through the entire small bowel
segment. This aluminum concentration was selected to repre-
sent the maximum concentration of solubilized aluminum in the
gastric contents following a dose of an aluminum-containing
phosphate binding agent. During perfusion the pH increased to
5.5 and a precipitate formed. The perfusate was centrifuged and
the supernatant discarded. A portion of the precipitate was
washed with absolute methanol to minimize the development of
crystallinity [24] and dried at room temperature over desiccant.
The dried precipitate was prepared for infrared spectroscopy
by grinding with oven-dried potassium bromide. The resultant
fine powder was then compressed into a pellet. Infrared spectra
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(IR-33, Beckman Instruments, Fullerton, California, USA)
were recorded from 4000 to 600 cm'.
In a separate series of experiments, 25 ml of perfusate
containing 2.5 X i0 M Aid3 or 2.5 X l0 M AICI3 and 2.5 x
iO— M sodium citrate were adjusted to pH 6.0 and circulated
through the entire small bowel segment, as before. The pH of
the perfusate within the beaker was continuously monitored
and maintained within 0.1 units by a pH-stat titrator (PHM 62,
ITT 60, ABU 12 [2.5 ml], TTA 60, REA 160, Radiometer,
Copenhagen, Denmark).
Blood samples were collected via a cannula inserted into the
right carotid artery of heparinized animals. Samples were
collected before perfusion in order to establish baseline plasma
aluminum values, then at intervals over the course of the
perfusions. Samples were centrifuged, then diluted with an
equal volume of solution containing 0.1% Triton X-l00 (Sigma
Chemical Company, St. Louis, Missouri, USA) and 1.4 g/liter
magnesium nitrate. Plasma samples were analyzed in triplicate
by electrothermal atomic absorption spectroscopy (Atomic
absorption spectrophotometer model 560, programmer model
HGA 500 and graphite furnace model HGA 500, Perkin Elmer,
Norwalk, Connecticut, USA), using a method adapted from the
literature [251.
A reference aluminum solution (1000 /hg/ml, Fisher) was used
to prepare fresh aluminum standards daily. A typical calibration
curve was linear with a correlation coefficient (r2) value of 0.99.
The analytical method was validated by standard addition of
aluminum to plasma. The measured aluminum concentration
was linearly related to the theoretical aluminum content, having
an r2 value of 0.99.
The effect of selected dietary constituents on the pH of
precipitation was determined by titrating a 0.1 M aluminum
chloride solution containing 0.3 M dietary constituent of interest
with 0.1 N NaOH using an automatic titrator (Radiometer).
Titrant addition was continued until a precipitate was visually
observed.
Results
Aluminum-containing phosphate binding agents are chemi-
cally a form of aluminum hydroxide. As seen in Figure 1, they
exhibit a high solubility in gastric acid, producing soluble
Al(0H2)63 by equation I. This soluble species is then trans-
ferred to the small intestine by gastric emptying.
Al(OH)3 + 3 H30 —* Al(0H2)63 (eq. I)
Aluminum chloride was selected as a model for the form of
aluminum which is produced in gastric acid because aluminum
chloride dissociates in aqueous solution to produce Al(0H2)63
by equation 2.
Aid3 + 6 H20 Al(0H,)63 + 3Cl
However, aluminum is particularly insoluble at neutral pH as a
result of the formation of stable hydroxide complexes [26]
which limit the solubility of aluminum to less than I m/ml at
pH 6 (Fig. I). Thus, aluminum cations solubilized by gastric
acid are expected to precipitate in the intestine as a result of the
increased pH. This hypothesis was examined by perfusing 25 ml
of a 2.5 x 10—2 M aluminum chloride solution through the in situ
intestinal segment. The pH of the aluminum chloride solution
initially was 3.2 and was not controlled during perfusion. The
pH of the perfusate was monitored and, as expected, steadily
increased. Perfusion was continued for 180 minutes, at which
time the pH of the perfusate was 5,5. A precipitate was
observed in the perfusate, the infrared spectrum of which is
presented in Figure 2. The spectrum contains broad 0-H
stretching bands at 3400 cm, which are attributed to amor-
phous aluminum hydroxide [27]. This broad band is consistent
with the expected slow development of crystallinity in freshly
precipitated materials. The prominent water band at 1635 cm'
represents water strongly bound at the solid surface or ad-
sorbed during sample preparation. The strong water band and
the broad hydroxyl-stretching band both suggest that the pre-
cipitate has a high surface area. Broad bands at 965 and 1060
cm' indicate that phosphate is also a component of the
precipitate. This observation is consistent with the use of
aluminum hydroxide as a phosphate binding gel [22]. Likewise,
the bands at 1420 and 1525 cm are attributed to carbonate.
The infrared spectrum identifies the precipitate as amorphous
aluminum hydroxyphosphate carbonate. Thus, the phosphate
and bicarbonate ions present in the intestinal lumen are incor-
porated into the amorphous aluminum hydroxide which precip-
itates in the intestine as a result of the elevated pH.
The effect of perfusion with freshly precipitated amorphous
aluminum hydroxide on the intestinal absorption of aluminum
was investigated by circulating a 2.5 x l0 M aluminum
(e 2) chloride-containing perfusate through the in situ intestinal seg-q. ment for 50 minutes, The pH was maintained at 6.0 by the pH
stat titrator. Plasma aluminum levels measured over the course
of these perfusion experiments are shown in Figure 3, Curve A.
The data represent the mean and standard deviation of perfu-
sion in three rats. These experiments indicate no statistically
significant (P < 0.05) increase in plasma aluminum levels
compared to the values measured before perfusion was begun.
Thus, precipitated aluminum hydroxide present in the intestine
is not absorbed. This conclusion was confirmed by perfusing a
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Fig. 1. Effect of pH on the equilibrium solubility of microcrystalline
aluminum hydroxide at 25°C. From reference 26.
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Fig. 3. Average plasma aluminum levels (N = 3, SD) wit/i thne for
perfusions with: A, 2.5 X I0 M aluminum chloride-containing peifus-
ate at pH 6; B, 2.5 X I0 M aluminum chloride and 2.5 X l0 M
sodium citrate-containing pe,fusate at pH 6.
suspension of a commercial amorphous aluminum hydroxide
containing 2.5 X iO M aluminum at pH 6 through the in situ
intestinal segment. The results were identical to Figure 3, Curve
A, indicating no aluminum absorption.
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Absorption of citrate-chelated aluminum, a complex which is
soluble at the pH of the intestine, was investigated. Solutions
equimolar in aluminum chloride and sodium citrate were pre-
pared, adjusted to pH 6.0 and perfused through the in situ rat
gut as before. Plasma aluminum levels in this experiment are
shown in Figure 3, Curve B, and illustrate that perfusion with
citrate-chelated aluminum species resulted in a statistically
significant (P < 0.05) sixfold elevation in plasma aluminum
levels above baseline values. From this data, it is apparent that
the form of aluminum ultimately present in the intestinal lumen
has a significant effect on the absorption of aluminum. While
insoluble amorphous aluminum hydroxide present in the per-
fusate did not result in significant increases in plasma aluminum
levels, soluble citrate-chelated aluminum species were ab-
sorbed.
Aluminum hydroxide normally precipitates at pH 4.5 when
an aluminum chloride solution is titrated with sodium hydrox-
ide. However, a number of chemicals present in the diet were
found to inhibit precipitation. Table I lists the dietary chemicals
which were found to prevent precipitation at the pH conditions
expected in the intestine.
Discussion
These experiments illustrate the importance of the form of
aluminum that ultimately reaches the absorptive surfaces of the
intestinal mucosa on the resultant plasma aluminum levels.
When aluminum cations, Al(OH2)63, produced by the disso-
lution of aluminum hydroxide in gastric fluid, encounter the
buffered secretions of the intestine, amorphous aluminum hy-
droxyphosphate carbonate is precipitated. As insoluble species
present in the gastrointestinal lumen are not absorbed, this
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Fig. 2. Infrared spectrum of the precipitate formed in time in situ intestinal segment during perfusion of a perfusate containing 2.5 x 10-2 M
aluminum chloride. The broad band centered at 3400cm' is attributed to amorphous aluminum hydroxide; the band at 1635 cm is adsorbed
water due to the high surface area; bands at 1420 and 1525 cm' are assigned to carbonate; the bands at 965 and 1060 cm' areassigned to
phosphate.
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Table 1. Compounds present in the diet which elevate the pH of
precipitation above 8 during the titration of 0.1 M aluminum chloride
with 0.1 N sodium hydroxide
Compound Dietary source
Ascorbic acid Citrus fruits, food additive: antioxidant
Citric acid Citrus fruits, food additive: acidulent
Gluconic acid Food additive: sequestering agent
Lactic acid Sour foods, molasses, food additive:
acidulent
Malic acid Apples and other fruits, food additive:
acidulent
Oxalic acid Rhubarb, beets
Tartaric acid Grapes and other fruits, food additive:
acidulent
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